Ozempic vs Wegovy vs Rybelsus — Semaglutide Brand Comparison

Ozempic, Wegovy, and Rybelsus are three different brand names for the same active molecule: semaglutide. Novo Nordisk markets them differently because regulatory indications, dose ranges, and routes of administration differ. From a research perspective, knowing what separates them clarifies the published trial data and avoids confusion.

The shared molecule

All three contain semaglutide — a long-acting GLP-1 receptor agonist with a ~7-day plasma half-life. The molecular structure is identical across the brands. What differs is dose strength, route, and approved use.

Ozempic — the diabetes brand

Attribute	Detail
Indication	Type 2 diabetes
Route	Subcutaneous injection, weekly
Dose range	0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg weekly
Trial programme	SUSTAIN (diabetes endpoints)

The maximum approved dose for Ozempic is 2.0 mg weekly. Weight loss is a documented side effect but not the primary endpoint.

Wegovy — the weight-management brand

Attribute	Detail
Indication	Chronic weight management in obesity
Route	Subcutaneous injection, weekly
Dose range	0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly
Trial programme	STEP (weight-loss endpoints)

Wegovy reaches a higher maximum dose (2.4 mg) than Ozempic. The STEP trial programme established the ~14.9% weight loss endpoint that drives the brand’s positioning.

Rybelsus — the oral tablet

Attribute	Detail
Indication	Type 2 diabetes
Route	Oral tablet, daily
Dose range	3 mg → 7 mg → 14 mg daily
Trial programme	PIONEER

Rybelsus is the only oral GLP-1 agonist on the market. Oral bioavailability of peptides is normally near-zero — Rybelsus solves this with a co-formulated absorption enhancer (SNAC, sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) that opens gastric tight junctions. Bioavailability remains low (~1%), which is why oral doses are 14 mg versus subcutaneous 2.4 mg.

Why the same molecule needs three brands

Regulatory approvals in many countries are indication-specific. A medication approved for diabetes cannot be marketed for weight loss without a separate trial programme and approval. Novo Nordisk ran the SUSTAIN trials for diabetes (→ Ozempic, oral version → Rybelsus) and the STEP trials for weight management (→ Wegovy). Same molecule, three approved use cases, three brand names.

Practical research implications

For researchers studying semaglutide:

Subcutaneous research at weight-management-equivalent doses references the 2.4 mg weekly endpoint
Subcutaneous research at diabetes-equivalent doses uses the 1–2 mg range
Oral research is conceptually distinct — bioavailability limits create different pharmacokinetic profiles

What this means for catalogue listings

Research peptide catalogues list “semaglutide” — the molecule. The brand names are regulatory and marketing constructs. Chempeptides supplies HPLC-verified semaglutide with batch CoA — see the catalogue for current availability and the Ozempic mechanism article for trial data depth.

Research use only.

Gerelateerd onderzoek

Research disclaimer▾

Alle informatie op deze pagina is bedoeld voor laboratoriumonderzoek en in-vitro studies. Geen humane consumptie. Geen medische claims. Producten zijn niet goedgekeurd door EMA of FDA voor therapeutisch gebruik.

Blogs